Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 14, 2021 - Issue
Submit an article Journal homepage
125
Views
7
CrossRef citations to date
0
Altmetric
Case Report

Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy

Taoming LiuDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Juan BaiDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Su WangDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Shuni YingDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Sheng LiDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4641-7907
ORCID Icon,
Jianjun QiaoDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-3386-297X
ORCID Icon &
Hong FangDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
 show all
Pages 175-178 | Published online: 04 Mar 2021

References

  • Huang AH, Canner JK, Kang S, Kwatra SG. Analysis of real-world treatment patterns in patients with prurigo nodularis. J Am Acad Dermatol. 2020;82(1):34–36. doi:10.1016/j.jaad.2019.09.007
  • Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567–1575. doi:10.1016/j.jaad.2020.04.182
  • Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706–716. doi:10.1056/NEJMoa1908316
  • Park K, Mori T, Nakamura M, Tokura Y. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur J Dermatol. 2011;21(1):135–136. doi:10.1684/ejd.2010.1196
  • Zhong W, Wu X, Zhang W, et al. Aberrant expression of histamine-independent pruritogenic mediators in keratinocytes may be involved in the pathogenesis of prurigo nodularis. Acta Derm Venereol. 2019;99(6):579–586. doi:10.2340/00015555-3150
  • Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi:10.1056/NEJMoa1314768
  • Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155(1):118–120. doi:10.1001/jamadermatol.2018.3912
  • Giura MT, Viola R, Fierro MT, Ribero S, Ortoncelli M. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020;33(1):e13201. doi:10.1111/dth.13201
  • Kovács B, Rose E, Kuznik N, et al. Dupilumab for treatment-refractory prurigo nodularis. J Dtsch Dermatol Ges. 2020;18(6):618–624. doi:10.1111/ddg.14107
  • Criado PR, Pincelli TP, Criado RFJ. Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. Int J Dermatol. 2020;59(10):e358–e361. doi:10.1111/ijd.14994
  • Wieser JK, Mercurio MG, Somers K. Resolution of treatment-refractory prurigo nodularis with dupilumab: a case series. Cureus. 2020;12(6):e8737. doi:10.7759/cureus.8737

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.